Background-Hypertensive target organ damage, especially cardiac hypertrophy with heart failure and arrhythmia, is a major source of morbidity and mortality. Angiotensin II, a major mediator of hypertension and cardiac damage, has proinflammatory properties. Inflammation and activation of the immune system play a pivotal role in pathogenesis of hypertensive target organ damage. However, the role of immunosuppressive CD4 ϩ CD25 ϩ regulatory T (Treg) cells in the pathogenesis of hypertensive target organ damage is unexplored. Methods and Results-We conducted adoptive transfer of Treg cells into angiotensin II-infused hypertensive mice. Treg cell recipients exhibited improved cardiac hypertrophy and less cardiac fibrosis despite sustained hypertension. Amelioration of cardiac morphology was accompanied by an improvement in arrhythmogenic electric remodeling, indicating the functional significance of the enhanced cardiac morphology. Delocalization of the connexin 43 gap junction protein is one of the major pathomechanisms in electric remodeling. Pronounced connexin 43 immunoreactivity was found at the lateral borders of cardiomyocytes in angiotensin II-treated mice. In contrast, connexin 43 was restricted to the intercalated disk regions in sham controls. Surprisingly, angiotensin IIϩTreg-treated mice showed normal connexin 43 gap junction protein localization. Adoptive Treg cell transfer resulted in a marked reduction in cardiac CD4 ϩ , CD8 ϩ , and CD69 ϩ cell and macrophage infiltration. Conclusions-Immunosuppressive effects of transferred Treg cells ameliorated cardiac damage and accounted for the improved electric remodeling independently of blood pressure-lowering effects. Our results provide new insights into the pathogenesis of hypertensive cardiac damage and could therefore lead to new therapeutic approaches that involve manipulation of the immune system. (Circulation. 2009;119:2904-2912.)
H ypertension is a major risk factor for cardiovascular disease, stroke, and chronic renal failure. Furthermore, hypertension promotes left ventricular (LV) hypertrophy, enhancing the incidence of heart failure and ventricular arrhythmias. [1] [2] [3] Target organ damage is the result of blood pressure-dependent biomechanical strain and blood pressure-independent effects of several hormones and neurotransmitters, particularly angiotensin II (Ang II). Aside from the physiological role of Ang II in maintaining blood pressure and electrolyte/fluid homeostasis, Ang II induces inflammation and fibrosis and thereby contributes to target organ damage. 4, 5 The renin-angiotensin system also is linked to the immune system. T cells, macrophages, and dendritic cells all express the Ang II AT1 receptor. Ang II stimulates T-cell proliferation and dendritic cell migration. 6 -8 In mice, sustained Ang II infusion elevates the number of circulating CD4 ϩ T cells harboring the early activation marker CD69, as well as the tissue-homing proteins CD44 and CCR5. 9 In addition, numerous in vitro and in vivo studies demonstrated that Ang II activates nuclear factor-B, a major transcription factor mediating inflammation and innate immunity. Our group showed that nuclear factor-B inhibition reduced cardiac hypertrophy and albuminuria in double-transgenic rats expressing high levels of renin and angiotensinogen (dTGR). 4 Furthermore, we and others showed that various antiinflammatory and immunosuppressive interventions reduced Ang II-induced hypertensive target organ damage. 8, 10, 11 
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Regulatory T (Treg) cells are a CD4 ϩ T-cell subpopulation that has the capacity to suppress immune responses to autoantigens, alloantigens, tumor antigens, and infectious agents, thereby substantially contributing to the maintenance of immunologic self-tolerance and immune homeostasis. 12 Depletion of Treg cells results in autoimmune disease, whereas restoring and expanding the Treg cell compartment was beneficial in several animal models of immune-mediated diseases. 13, 14 Their characteristic marker, the transcription factor Foxp3, largely controls the phenotype and function of Treg cells. 15 Apart from their ability to suppress other T cells, Treg cells can suppress macrophages and dendritic cells. 16, 17 Because the activation of T lymphocytes seems to play a pivotal role in Ang II-induced target organ damage and because immunosuppressive treatment was shown to be beneficial in Ang II-induced target organ damage, we tested the hypothesis that the immunosuppressive effects of adoptively transferred Treg cells could interfere with Ang IIinduced inflammatory and immune response and thereby ameliorate cardiac target organ damage.
Methods

Experimental Animals and Study Design
Eleven-week-old male NMRI mice (Charles Rivers Laboratories, Wilmington, Mass) were used throughout the study. We followed the American Physiological Society guidelines for animal care, and the Berlin Animal Review Board approved all protocols (G125/07). Ang II (1.44 mg · kg Ϫ1 · d Ϫ1 ) was continuously delivered by a subcutaneously implanted osmotic pump (nϭ20) (ALZET Osmotic pumps, DURECT Corporation, Cupertino, Calif). One day after the beginning of the Ang II infusion, one group of mice received 2ϫ10 5 Treg cells intravenously (nϭ15). Sham control mice received saline (nϭ22). In some experiments, another group of Ang II mice received 2ϫ10 5 CD4 ϩ CD25 Ϫ T cells (nϭ15). Six-week-old male mice served as Treg and CD4 ϩ CD25 Ϫ cell donors. Mean arterial blood pressure was measured by radiotelemetry (Ang II, nϭ4; Ang IIϩTreg, nϭ4). Cardiac morphology was assessed by echocardiography on day 11 (Ang II, nϭ17; Ang IIϩTreg, nϭ10; sham controls, nϭ22). In a subset of experiments, programmed electric stimulation was conducted on day 14 (number of completed protocols: Ang II, nϭ13; Ang IIϩTreg, nϭ13; sham controls, nϭ14; number of animals studied: Ang II, nϭ5; Ang IIϩTreg, nϭ5; sham controls, nϭ5). After a total of 2 weeks, animals were killed, and their blood and organs were collected for further analysis.
Isolation of Treg and CD4 ؉ CD25 ؊ T Cells
Treg cells and CD4 ϩ CD25 Ϫ T cells were obtained with the Miltenyi Biotech (Bergisch Gladbach, Germany) isolation kit and fluorescence-activated cell sorting as described in detail in the online-only Data Supplement.
Echocardiographic Assessment of Cardiac Hypertrophy
Intraventricular septal and LV posterior wall thickness and LV mass were estimated. For details, see the online-only Data Supplement.
In Vivo Electrophysiology Studies
ECG standard intervals were measured in 6-limb leads. To test for inducibility of arrhythmias, programmed ventricular stimulation protocols were used. For details, see the online-only Data Supplement.
Histology and Immunohistochemistry
Sirius red staining was performed on paraffin-embedded heart sections. Cryosections were stained with immunofluorescence techniques. For the detailed protocol, see the online-only Data Supplement.
Quantitative TaqMan Reverse-Transcription Polymerase Chain Reaction
Total cardiac LV RNA, Treg, and CD4 ϩ CD25 Ϫ T-cell RNA was isolated with TRIZOL followed by the Qiagen protocol, and TaqMan reverse-transcription polymerase chain reaction was performed. 18 The sequences of the primers are given in the online-only Data Supplement.
Flow Cytometric Analysis of Splenic Lymphocytes
Spleens of Ang II, Ang IIϩTreg, and sham control mice were harvested at the time of death. After osmotic lysis of red blood cells, cells in single-cell suspension were stained with anti-CD4 (GK1.5), anti-62L (MEL-14), and anti-CD44 (IM7) (BD Biosciences, San Jose, Calif). Cells were analyzed with the LSR-II flow cytometer with FACSDiva software (BD Biosciences, San Jose, Calif). Data were analyzed with FlowJo software (Tree Star, Ashland, Ore).
In Vitro Suppression Assay
Responder CD4 ϩ CD25 Ϫ T cells were stimulated with soluble anti-CD3 and antigen presenting cells in the presence or absence of Treg cells according to the protocol given in the online-only Data Supplement.
Statistical Analysis
Data are presented as meanϮSEM. Statistical significance of the differences in mean values was tested by ANOVA. If significance was indicated, the Bonferroni posthoc test was used to discern differences between specific groups. For electric stimulations, the Kruskal-Wallis test, followed by pairwise posthoc 2 test and Bonferroni correction for multiple comparisons, was applied. Data were analyzed with GraphPad Prism software (GraphPad Software, La Jolla, Calif).
Results
Adoptive Transfer of Treg Cells Attenuates Ang II-Induced Cardiac Hypertrophy and Fibrosis
Sustained Ang II infusion leads to cardiac hypertrophy in NMRI mice. LV hypertrophy index, expressed as the ratio of echocardiographically estimated LV weight to body weight, was increased in Ang II-treated animals (4.57Ϯ0.16 versus 3.36Ϯ0.10 mg/g in sham control mice; PϽ0.05). Ang IItreated animals that received Treg cells (Ang IIϩTreg) exhibited significantly lower cardiac hypertrophy index (3.87Ϯ0.27 mg/g; PϽ0.05 versus Ang II-treated mice; Figure 1A) . Diastolic wall dimensions (interventricular septum and left posterior wall diameter) were increased after sustained Ang II infusion (1.96Ϯ0.04 versus 1.57Ϯ0.04 mm in sham control mice; PϽ0.05) and reduced to 1.73Ϯ0.06 mm in Treg cell recipient mice (PϽ0.05 versus Ang II-treated mice; Figure 1B ). In addition, cardiac mRNA expression of hypertrophy marker brain natriuretic peptide was significantly increased after sustained Ang II infusion compared with sham control mice (6.37Ϯ0.67 versus 2.10Ϯ0.36 arbitrary units [a.u.], respectively; PϽ0.05) and significantly reduced in mice that received Treg cells (3.10Ϯ0.50 a.u.; PϽ0.05 versus Ang II-treated animals; Figure 1C ).
To confirm that the observed effects rely exclusively on transfer of CD4 ϩ CD25 ϩ Treg cells and not of another CD4 ϩ T-cell subpopulation, we also transferred CD4 ϩ CD25 Ϫ effector T cells into Ang II-treated mice. Flow cytometric sorting strategy and analysis of Foxp3 expression in sorted Treg cells and CD4 ϩ CD25 Ϫ cells are shown in Figure I of the online-only Data Supplement. The percentage of Foxp3 ϩ cells among CD4 ϩ CD25 ϩ cells was always Ͼ75%, whereas only minimal numbers of Foxp3 ϩ cells (Ͻ3%) among CD4 ϩ CD25 Ϫ cells could be detected. Cardiac hypertrophy index, determined as the ratio of heart weight to body weight, was significantly increased in Ang II-treated mice and mice that received CD4 ϩ CD25 Ϫ T cells (5.37Ϯ0.13 and 5.18Ϯ0.17 mg/g, respectively; PϾ0.05) compared with Ang IIϩTreg mice and sham controls (4.90Ϯ0.13 and 3.97Ϯ0.06 mg/g, respectively; PϽ0.05 versus Ang II-treated mice; Figure 1D ). The data indicate that transfer of Treg cells, but not of CD4 ϩ CD25 Ϫ effector T cells, improved cardiac hypertrophy.
To examine whether cardiac hypertrophy was accompanied by extracellular matrix deposition, histological analysis of Sirius red-stained heart sections was performed, as shown in Figure  2A . Semiquantitative scoring of interstitial and perivascular cardiac fibrosis demonstrated a significantly increased degree of fibrosis in Ang II-infused mice compared with Ang IIϩTreg mice and sham controls (4.17Ϯ0.61 versus 2.18Ϯ0.47 versus 0.56Ϯ0.17 a.u., respectively; PϽ0.05; Figure 2B ).
Ang II-Induced Electric Remodeling Is Diminished in Treg Cell Recipients
To investigate functional implications of the effects of Treg cell transfer on cardiac morphology, we investigated the susceptibility to ventricular arrhythmias using programmed electric stimulation. Sustained Ang II infusion rendered mice prone to ventricular arrhythmias. Reproducible nonsustained ventricular arrhythmias were elicited in 69% of Ang IItreated mice, whereas Ang IIϩTreg-treated animals showed a significantly reduced induction rate similar to sham controls (23% for Ang IIϩTreg-treated mice versus 21% for sham controls; PϽ0.05 versus Ang II-treated mice; Figure 3A ). Representative recordings of performed electrophysiological studies are shown in Figure 3B . Delocalization of the con- nexin 43 (Cx43) gap junction protein is one of the major pathogenic mechanisms in electric remodeling. Pronounced Cx43 immunoreactivity was found at the lateral borders of cardiomyocytes in Ang II-treated mice. In contrast, Cx43 was restricted to the intercalated disk regions in sham controls. Surprisingly, Ang IIϩTreg-treated mice showed normal Cx43 gap junction protein localization ( Figure 3C ).
Adoptive Transfer of Treg Cells Has No Impact on Ang II-Induced Arterial Hypertension
T cells play a role in the genesis of hypertension. 9 To investigate the effect of Treg cell transfer on Ang II-induced hypertensive response, we performed continuous radiotelemetric measurement of the mean arterial blood pressure. Before Ang II treatment, both groups were normotensive (110Ϯ2 versus 111Ϯ2 mm Hg, respectively; Figure 4 ). Sustained Ang II infusion raised the mean arterial blood pressure by 40 mm Hg. In our small samples, no difference in mean arterial blood pressure was observed between Ang II-treated mice and Ang IIϩTreg-treated mice (151Ϯ7 versus 149Ϯ8 mm Hg, respectively; PϾ0.05; Figure 4 ). Hence, transfer of Treg cells has no influence on Ang II-induced hypertension. Therefore, all the effects of adoptive Treg cell transfer shown in the present study are independent of blood pressure.
Adoptive Transfer of Treg Cells Diminishes Ang II-Induced Activation of the Immune System
Because it was recently shown that sustained Ang II infusion increases the percentage of circulating activated or effector memory T cells, 9 we next focused on the effects of Treg cell transfer on Ang II-induced activation of immune system and inflammation. Fluorescence-activated cell sorter analysis of splenic lymphocytes isolated from animals after sustained Ang II infusion revealed an increase in the number of CD4 ϩ T cells expressing high levels of CD44 and low levels of CD62L (CD44 high CD62L low ), characteristic of activated or effector memory T cells. Treg cell recipients showed a diminished increase in number of activated or effector memory T cells, implicating a systemic immunosuppressant effect of Treg cell transfer. Representative flow cytometric plots are shown in Figure 5 . 
Ang II-Induced Cardiac Inflammation Is Reduced in Treg Cell Recipients
Cardiac inflammation not only is a morphological feature of Ang II-induced cardiac damage but also might be involved in the development of cardiac hypertrophy because mice devoid of tumor necrosis factor-␣ (TNF␣) develop less prominent cardiac hypertrophy on induction of aortic stenosis. 19 To gain insight into the extent of ongoing cardiac inflammation, we next analyzed cell infiltration in the heart. Infiltrating monocytes/macrophages, CD4 ϩ and CD8 ϩ T cells, activated CD69 ϩ cells ( Figure 6A ), and TNF␣ protein expression ( Figure 6B and 6C) were determined by immunofluorescent stains. Semiquantitative analysis revealed distinct CD4 ϩ and CD8 ϩ T-cell and macrophage infiltration in the heart after sustained Ang II infusion. Ang II-treated animals also exhibited cardiac CD69 ϩ cell infiltrates and pronounced TNF␣ expression in the media of small cardiac vessels. Treg cell recipients exhibited significantly reduced inflammatory cell infiltrates and TNF␣ expression ( Figure 6A through 6D ).
Gene Expression of Renin-Angiotensin System Components in Treg and CD4 ؉ CD25 ؊ Cells
The AT1 B , AT2, (pro)renin receptor, and angiotensin-converting enzyme gene were expressed in Treg and CD4 ϩ CD25 Ϫ T cells, whereas AT1 A receptor, angiotensinogen, renin, and the angiotensin-converting enzyme-2 gene were absent ( Figure II 
Influence of Ang II on Suppressive Capacity of Treg Cells
Because Ang II-induced hypertensive cardiac damage is characterized by pronounced inflammatory phenotype, we considered the possibility that Ang II reduced the suppressive ability of Treg cells and thereby aggravated the target organ damage. Therefore, we investigated whether Ang II affected the suppressive capacity of Treg cells using a suppression assay with Treg cells treated in vitro with Ang II ( Figure 7A ) and Treg cells isolated from chronically Ang II-infused or control mice ( Figure 7B ). Neither in vitro exposure to Ang II nor sustained Ang II infusion decreased the capacity of Treg cells to inhibit T-responder cell proliferation.
Discussion
The major finding of the present study is that Treg cell transfer ameliorates Ang II-induced cardiac damage. The results demonstrate that Treg cell transfer reduced cardiac hypertrophy and fibrosis. Treg cell recipients exhibited a significant reduction in cardiac inflammation characterized by reduced inflammatory infiltrates and reduced TNF␣ expression. Treg cell transfer did not affect the development of hypertension, indicating that the cardiac protection was blood pressure independent. Our study also provides the first evidence that Treg cells improve electric remodeling in hypertension/Ang II-induced cardiac damage.
Hypertension is a major risk factor for cardiovascular events. In general, it is well accepted that the vasculature, kidney, and nervous system play a crucial role in hemodynamic alterations initiated by Ang II. 20 -22 Interestingly, Guzik et al 9 very recently linked the immune system to the regula- tion of blood pressure. They demonstrated that mice lacking T and B cells (RAG-1 Ϫ/Ϫ mice) exhibited blunted blood pressure response to Ang II infusion and that adoptive transfer of T cells restored the hypertensive Ang II response, whereas B-cell transfer had no effect of blood pressure. In the present study, Ang II-treated mice with adoptive Treg cell transfer were as hypertensive as Ang II-treated controls. These findings underscore the notion that Treg cell-mediated protection is independent of any modulating effects on blood pressure. Nevertheless, high blood pressure is not the sole factor in the pathogenesis of target organ damage. Numerous blood pressure-independent mechanisms contribute to hypertensive target organ damage. We reported earlier that aspirin inhibited nuclear factor-B activity and reduced cardiac hypertrophy in an Ang II-dependent rat model despite blood pressures exceeding 170 mm Hg. 23 The major finding in our study is the beneficial influence of Treg cell transfer on electric remodeling because Treg cell recipients were less susceptible to inducible ventricular tachycardia. These findings accentuate the functional relevance of reduced cardiac hypertrophy in Treg cell recipients. Cardiac hypertrophy causes electric remodeling, including nonuniform action potential prolongation, altered repolarization with increased recovery dispersion, and the generation of afterpotentials. All these alterations contribute to increased vulnerability to ventricular arrhythmias and sudden cardiac death. 24, 25 Experimental studies indicate that a reduction in cardiac hypertrophy improves electric remodeling independently of specific medical treatment. 26, 27 However, clinical trials provide the most direct evidence on sudden cardiac death. A posthoc analysis of the Losartan Intervention for End Point Reduction in Hypertension (LIFE) trial supports this notion because the absence of ECG signs of cardiac hypertrophy was associated with a significant reduction in the risk of sudden cardiac death independently of treatment modality, blood pressure reduction, and other cardiovascular risk factors. 28 Furthermore, the Randomized Aldactone Evaluation Study (RALES), an aldosterone antagonist treatment in heart failure trial, suggested that both cardiac hypertrophy and reduced matrix turnover were important in reducing sudden cardiac death. 29 Inflammation also may promote electric remodeling and thereby increase the risk of arrhythmias, as shown in mice cardiac-restricted TNF␣ overexpression, although definite clinical correlates, along the lines of LIFE and RALES, have not yet been provided. 30, 31 The importance of naturally occurring Treg cells in maintaining immunologic tolerance to self-and non-self-antigens and controlling immune responses during infections is well established. 32 Adoptive Treg cell transfer was beneficial in animal models of immune-mediated diseases such as encephalomyelitis, diabetes, and arthritis, as well as in transplantation and renal disease models. 13, 16, [33] [34] [35] [36] Recent advances in our understanding of cardiovascular disease-related mechanisms such as hypertensive target organ damage and atherosclerosis underscore the key role of inflammation and immunity. 37, 38 Ang II, one of the major mediators of hypertensive target organ damage, is a powerful promoter of inflammation and is able to activate the immune system. In mice, sustained Ang II infusion elevates the number of circulating CD4 ϩexpressing lymphocytes harboring the early activation marker CD69, as well as tissue-homing proteins CD44 and CCR5. 9 We showed previously that severely hypertensive dTGR rats, outfitted with the human renin and angiotensinogen genes, develop cardiac hypertrophy and renal damage. dTGR rats exhibit marked inflammatory responses with increased expression of adhesion molecules and inflammatory cytokines. Blockade of the renin-angiotensin system prevented inflammation and target organ damage. 39 Furthermore, immunosuppression ameliorated target organ damage in this model; dexamethasone did so entirely independently of blood pressure. 8 Experimental and clinical evidence shows that blockade of the renin-angiotensin system in atherosclerosis results in decreased inflammation and plaque progression. 40 Recently, the first data on the role of Treg cells in cardiovascular diseases were published. Ait-Oufella et al 41 showed that the transfer of splenocytes deficient in Treg cells accelerated the progression of atherosclerosis, whereas cotransfer of Treg cells abrogated the development of atherosclerosis. Furthermore, depletion of Treg cells increased the lesion size and increased the accumulation of macrophages and T cells, indicating enhanced plaque inflammation. Along these lines, Mor and coworkers 42 also demonstrated that Treg cell transfer resulted in a significant attenuation of atherosclerosis.
In the present study, we have shown that the amelioration of cardiac damage with Treg cell transfer was accompanied by reduced cardiac cell infiltration and a diminished number of activated splenic CD4 ϩ cells. Because Treg cell transfer seems to influence the abundance of activated splenic T cells and activated immune cells in the heart, we speculate that adoptive Treg cell transfer might inhibit the activation of immune cells and their migration from peripheral lymph tissues into the heart. We cannot rule out a local role of transferred Treg cells within the heart. Surprisingly, mice treated with Ang II or with Ang IIϩTreg had increased Foxp3 infiltration in the heart, whereas no Foxp3 ϩ cells were observed in control hearts (data not shown). Treg cells have a long lifespan. Possibly, Ang II initiates a chemoattractant signaling in endogenous Treg cells that initiates cardiac accumulation in the early phase of the disease, which persists independently of subsequently transferred Treg cells. It is a matter of debate whether Treg cell action in the different models occurs locally at the site of disease or instead within draining lymph nodes. In animal models with autoimmune diabetes, transferred Treg cells accumulated in lymphatic tissues rather than directly at the site of inflammation, 33 whereas in experimental autoimmune encephalomyelitis, Treg cells accumulate directly at the site of inflammation in the central nervous system. 43, 44 However, in mice with collagen-induced arthritis, transferred Treg cells could be detected in synovia and in lymphatic tissue. 34 We also performed cell-tracing experiments with carboxyfluorescein succinimidyl ester (CFSE)-labeled Treg cells but found no evidence that our adoptively transferred Treg cells accumulated in significant numbers in the heart (data not shown). We transferred naturally occurring Treg cells, which, according to published data, were capable of preventing disease in several mice models. 16, 34, 41 Nevertheless, in most studies, antigen-specific Treg cells were used, which allowed significantly smaller Treg cell numbers to suppress the disease. The use of such antigen-specific Treg cells is not possible in our . Influence of Ang II on suppressive activity of regulatory T cells. A, Representative flow cytometric histograms of CSFE dilution in the presence and absence of Ang II. Antigen presenting cells and CD4 ϩ CD25 Ϫ responder T cells were isolated from Ang II receptor type 1A-deficient mice (Agtr Ϫ/Ϫ ) used to exclude any Ang II effects on antigen presentation or responder T-cell proliferation. CSFElabeled CD4 ϩ CD25 Ϫ responder T cells were stimulated with anti-CD3. Treg cells isolated from wild-type mice were added at a ratio of 1:1 to the wells and cultured in the presence or absence of Ang II. No abrogation of suppressive activity of Treg cells exposed to Ang II was detected. B, Percentage of proliferation inhibition. In vitro suppression assay was performed as described above. Treg cells were added at the indicated ratio. No influence of Ang II on suppressive activity of Treg cells was observed. C, CD4 ϩ CD25 ϩ T cells were isolated from NMRI mice after 2 weeks of Ang II infusion and from control mice. Antigen presenting cells and CD4 ϩ CD25 Ϫ responder T cells were isolated from separate untreated mice. CSFE-labeled CD4 ϩ CD25 Ϫ responder T cells were stimulated with anti-CD3. Treg cells from Ang II-treated mice and control mice were added to wells at a ratio of 1:1. No difference in suppressive activity of Treg cells isolated from Ang II-treated and control mice was observed. model because the antigens responsible for T-cell activation in Ang II-induced cardiac damage are still unknown. 14 Impairment of Treg cell function was previously reported in several autoimmune diseases. 45 Because Treg cells posses the AT1 B and AT2 receptors, possible negative effects of sustained Ang II infusion on endogenous Treg cell function could have partly accounted for the target organ damage. In vitro suppression assay, however, showed normal activity of Treg cells that were exposed to Ang II either in vivo or in vitro. We therefore speculate that the observed effects in the present study rely on the balance shift between proinflammatory and antiinflammatory mechanisms in Ang II-induced inflammation.
Our findings reveal Treg cells as a new perspective in hypertension/Ang II-induced cardiac damage. Our results accentuate the inflammatory phenotype and underscore the importance of immune mechanisms and their modulation. We suggest that this new mechanistic information could be of future therapeutic relevance.
